Mylan (MYL) Surges on DOJ EpiPen Medicaid Rebate Settlement
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mylan (NASDAQ: MYL) is trading up 9% after-hours Friday after the company it agreed to the terms of a $465 million settlement with the DOJ and other government agencies that will resolve questions that have been raised about the classification of EpiPen for purposes of the Medicaid Drug Rebate Program.
The company's 2016 guidance was also cut, but very little.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verizon Communications (VZ) on call put ratio of 1 call to 2.2 puts into Q4
- Cree (CREE) call put ration 1 call for 1.8 puts into Q2 and outlook
- iPath S&P 500 VIX ST Futures ETN (VXX) down 16c to 20.57
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!